Every year we call out a “turkey” stock teaser around Thanksgiving time and poke a bit of fun at some terrible investment ideas… … so it seems only fair to highlight a few winners as well, and this week, when we’re getting ready to close down for the holiday, seems a good time to spread […]
Articles
I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
Today we’ve got a teaser pitch from Dylan Jovine’s new service, Takeover Targets, which he says is “half price” for charter subscribers (that would be $997/year, and unlike many higher-end newsletters they say they do offer refunds for 30 days)… and, as you might imagine, the service is all about identifying companies that might be […]
Here’s the lead-in to the ad that caught our readers’ attention this week: “This ‘Perfect Storm’ Stock Is Set to Deliver Big Pharma a Swift and Devastating DEATHBLOW It Won’t Come Back From… “And Launch This Little Company on A 72-Hour, $8.98 Billion All-Out SPRINT” And there’s a deadline… today, in fact, when there will […]
Happy Friday! Let’s start you out with my favorite article that I read this past week: Michael Batnick’s Twenty Craziest Investing Facts Ever. Go read it whenever you’re convinced that you know what is going to happen over the next few weeks… or even the next few years. So… what’s going on in the portfolio […]
This is an odd one, so be forewarned. A bunch of readers jumped in to ask me about emails coming out of Investorplace that pitch a tiny private company heading into FDA approval as the focus of their “Blockbuster FDA Approval Summit 2019” presentation… and yes, of course, the Mighty, Mighty Thinkolator can tell you […]
Ray Blanco makes (part of) his living looking for biotech moonshots, like most biotech-focused newsletter writers — and like his predecessor at Agora’s biotech and emerging tech-focused newsletter Breakthrough Technology Alert, he has often touted companies that are trying to end the scourge of Alzheimer’s Disease. Why? Well, two main reasons: First, and by far […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
You are right, all the clues do point to DNLI. But all the pieces for them to have it altogether in the Alzheimer field...
NTRP has just completed Phase 2 trials and seem to be very successful with their drug Bryo>>>> which is adm...
Believe NTRP is closer to Alzheimer cure with their Phase 2 trials just ready to be announced. Have invested in a small...
NTRP is more likely to make an Alzheimer's-related move this year than DNLI, I expect, though don't, of course, know if ...
Read Ray Blanco's Alzheimer's pitch also. Wasn't going to pay thousands for any newsletter.! Researched myself and ...
Researched after viewing Ray Blanco...think a promising company is NTRP just finished Phase 2 with FDA trials and will a...
Blanco is at it again. https://pro.sevenfiguresolutions.com/p/VPI_moneybrainv4_0719/EVPIV842/?a=13&o=138585&s=162274&u...
What is Blanco's latest. Is it DNLI?...
I wonder what the correlation is between the pumps and fund rasing by the companies. Naturally these types of companie...
Is this stock ESLAY or DNLI?...
i spent two hours sleuthing -- DNLI and ESALY were the only 2 public cos i found. KH MD...
Wish I'd known about you before I invested in DNLI. I bought the tease, as I am totally new to investing in stocks. I ...
Thank you Travis. You have confirmed my own research and conclusion on Blanco's "tiny" company as DNLI and done so with ...